Regulatory Issues in the Development of Drug Treatments for Various Psychiatric and Behavioral Disturbances Associated with Dementia Thomas Laughren, M.D. Team Leader, Psychiatric Drug Products Group Division of Neuropharmacological Drug Products FDA

6/13/00


Click here to start


Table of Contents

Regulatory Issues in the Development of Drug Treatments for Various Psychiatric and Behavioral Disturbances Associated with Dementia Thomas Laughren, M.D. Team Leader, Psychiatric Drug Products Group Division of Neuropharmacological Drug Products FDA

FDA Recognition of Clinical Spectrum in the Dementias

BPSD as Useful Concept

Author: CDER USER